Sun Nuclear Announces Landmark Update to Further Advance Radiation Therapy Workflows
Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK® software for comprehensive Quality Management in radiation therapy. The SunCHECK software is used globally by radiation therapy departments to manage delivery system oversight and patient-specific treatment quality --- all in one platform. SunCHECK Version 5.0 introduces a broad range of features and user-driven enhancements that optimize workflows and prioritize patient safety.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429991805/en/
Sun Nuclear, a Mirion Medical company, announced the upcoming version 5.0 release of its SunCHECK® software for comprehensive Quality Management in radiation therapy. SunCHECK v5.0 addresses clinical workflow challenges with new treatment plan assessment capabilities, enhanced TPS/OIS integration, expanded QA device control, and worklist-based UI. (Graphic: Business Wire)
The Connected Workspace for Higher Quality
Toward a vision of a truly connected ecosystem for quality assurance in radiation therapy, key enhancements in SunCHECK v5.0 include:
- Better, earlier understanding of treatment plan quality and departmental standards from new plan feasibility evaluation and plan complexity metric features
- Stronger continuity of clinical goals and data management when moving from linac treatment planning system (TPS)/oncology information system (OIS) into the SunCHECK software
- Automation of time-intensive machine quality measurements with expanded device integration with the PC Electrometer™ device and 1D SCANNER™ water tank
- At-a-glance worklists and intuitive patient and machine workflows reflected in the refreshed user interface
“In each new release of SunCHECK, we are connecting and accelerating clinical workflows, while expanding compatibility so clinicians can work effectively — regardless of their department structure or equipment. By delivering efficiency gains and easing access to critical insights on treatment quality, we can help clinicians better focus on advancing care,” said Luis Rivera, Sun Nuclear Radiation Therapy President.
Demonstrations of the latest software will be available in the Sun Nuclear booth (#930) at the ESTRO Annual Meeting, May 3-7, in Glasgow, Scotland. Sun Nuclear will host a lunch symposium, with a welcome from Tom Logan, Mirion CEO, on Sunday, May 5.
"I’m pleased to join my Sun Nuclear colleagues at ESTRO as we debut this landmark evolution of the SunCHECK software. This upcoming release is a significant leap forward, offering high impact functionality to support healthcare providers in delivering optimal care to patients,” said Tom Logan, CEO of Mirion.
Learn more about the SunCHECK platform here.
About Sun Nuclear
Sun Nuclear is part of Mirion Medical, a group of healthcare-focused brands within Mirion. We provide innovative solutions for Radiation Therapy and Diagnostic Imaging centers. More than 5,000 cancer centers worldwide rely on us for independent, integrated Quality Management. With a focus on ongoing support, Sun Nuclear aims to ease technology adoption, enhance workflows and improve outcomes – so that healthcare providers can achieve real results for Patient Safety. Visit us: sunnuclear.com. Follow us: @sunnuclear.
Sun Nuclear, SunCHECK, 1D SCANNER, and PC Electrometer are trademarks or registered trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429991805/en/
Contact information
For investor inquiries:
Jerry Estes
ir@mirion.com
For media inquiries:
Erin Schesny
media@mirion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom